Description:
ChromogenixCoamatic®Heparin isachromogenicassaykitforthequantitativedeterminationofunfractionatedheparin(UFHeparin)orlowmolecularweightheparin(LMWHeparin)inhumancitratedplasmausingautomatedandmicroplatemethods.
HeparinKitComposition:
Reagents, Packaging,Storage,StABIlityThesealedreagentsarestableat2-8°Cuntiltheexpirydateprintedonthelabel.
- S-2732™,15mg,2vials.Chromogenicsubstrate,Suc-Ile-Glu(-pip)-Gly-Arg-pNA·HCllyophilizedwithdetergentandmannitolasbulkingagent.Stabilityafterreconstitution:3monthsat+2-8°Cintheoriginalvial.Avoidexposuretolight.Discardthesubstratesolutionifitappearsyellow.Avoidcontaminationbymicroorganisms.
- FactorXa,35nkat,2vials.LyophilizedbovineFXacontainingTrisbuffer,EDTA,NaCl,dextransulfateandbovineserumalbumin.Stabilityafterreconstitution:3monthsat+2-8°Cintheoriginalvial.
MeasurementPrinciple:
| [AT •Heparin] | [FXa •AT •Heparin] | ||
| +FXa | → | ||
| S-2732™ | Peptide+pNA |
FactorXa(FXa)isaddedtoamixtureofundilutedplasmaandthechromogenicsubstrateS-2732™.WhenHeparinandATarecomplexed,twocompetingreactionsoccursimultaneously:
- InhibitionofFXabythe[AT·Heparin]complex.
- ReactionofFXawithS-2732™resultingincleavageofpNA.ThepNAreleasemeasuredat405nmisinverselyproportionaltotheheparinlevelinthesample.InordertoreducetheinfluencefromheparinantagoNISTs,suchasplateletfactor4(PF4),dextransulfateisincludedinthereactionmixture.
Background:
Heparinisthemostfrequentlyusedantithrombotictherapeutic.TheBIOLOGicalactivityofthissulfatedglycosaminoglycanresidesinitsabilitytoaccelerate(upto2000-fold)theinhibitoryeffectofantithrombin(AT)onthecoagulationproteases.TheamountofLMWHeparinorUFHeparinisdeterminedfromtheanti-FXaactivityexpressedbythe[AT·Heparin]complexformedinplasma.
Coamatic©Heparinmeasurestheabilityofheparintocatalyzetheinhibition ofFXabyantithrombin.Theanti-Xaassayisthemethodofchoicewhen monitoringLMWheparintherapyandisalsosuitableasareplacementfor theAPTTtestwhenmonitoringtherapywithUFHeparin.
SimplifiedHeparintesting,undilutedassaywithsuperiorreagentstability.
Readmoreaboutheparin.
